Skip to main content

Day: December 19, 2022

Webcomics Market to Hit USD 11.12 Billion by 2028 | Industry to Generate 6.1% CAGR during (2021-2028)

Written by Customer Service on . Posted in Mergers And Acquisitions.

Companies covered in Webcomics Market are Homestuck (United States), Penny Arcade Inc. (Redmond, WA, United States), The Oatmeal (Seattle, Washington, United States), Cucumber Quest (California, USA), Girl Genius (Seattle, WA, USA), Gunnerkrigg Court (Birmingham, United Kingdom), Stand Still, Stay Silent (Sweden), Brawl in the Family (United States), XKCD (United States), Lackadaisy (United States), Sandra and Woo (Germany), Scandinavia and the World (Denmark), and more players profiled. Pune, India, Dec. 19, 2022 (GLOBE NEWSWIRE) — According to Fortune Business Insights, the global webcomics market size is expected to gain momentum by reaching USD 11.12 billion by 2028 while exhibiting a CAGR of 6.1% between 2021 to 2028. In its report titled “Webcomics Market, 2021-2028,” Fortune Business Insights mentions that the...

Continue reading

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

Written by Customer Service on . Posted in Public Companies.

BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced results from its Phase 2 randomised, double-blind, placebo-controlled,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.